The Valve Wire sealThe Valve Wire
July 27, 2026E. Nolan Beckett, MD · Editor
LIVE · 06:50 ET · JUL 27, 2026
EW ▼ MDT ▲ ABT ▲ BSX ▲
Aortic Valve (TAVR/TAVI)Friday, July 24, 2026

Edwards Lifesciences beats quarterly estimates on strong demand for heart devices - WSAU

1 min read·By E. Nolan Beckett, MD·Source: WSAU
From The Valve Wire

Edwards' 13.6% Q2 TAVR sales growth and Venus Medtech's completed self-expanding pivotal enrollment reflect a market expanding faster than durability data can validate.

Three technique-focused papers signal where operators are spending their cognitive load: a Radiology: Cardiothoracic Imaging review on preprocedural CT for redo TAVR, a European Cardiology review of BASILICA , and a Future Cardiology review of direct TAVI vs predilatation .

All three are downstream consequences of the ESC 2025 lifetime-management mandate: coronary access, valve-in-valve feasibility, and commissural alignment must be planned at the index procedure.

Editor’s take pending for this article; this is the section commentary excerpt.
Source Abstract

Edwards Lifesciences beats quarterly estimates on strong demand for heart devices WSAU

Read the Original
Full article at WSAU
Open at WSAU
The Valve Wire summarizes; we link out to primary sources for verification.
More in Aortic Valve (TAVR/TAVI)
Elsewhere in Today’s Issue